Atlas Trials

A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Clinical trial NCT04592341 · TERMINATED

Trial details

NCT number
NCT04592341
Sponsor
Hoffmann-La Roche
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Alzheimer Disease
Start date
2020-11-18
Primary completion
2023-01-11
Enrollment
192

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.